Dostarlimab [DOS1]

Dostarlimab monotherapy for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) recurrent/advanced endometrial carcinoma after prior platinum-based chemotherapy where the following criteria have been met:

1. This application is being made by and also that the first cycle of systemic anti-cancer therapy with dostarlimab will be prescribed by a consultant, or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
2. The patient has a proven histological diagnosis of endometrial carcinoma. Please mark below whether the histology in this patient is endometrioid or not:

• the histology is of endometrioid type or
• the histology is of non-endometrioid type

3. The patient has recurrent or locally advanced or metastatic disease. Please mark below which of the following scenarios best describes the type of recurrent disease the patient has:

• the patient previously had a hysterectomy and relapsed with local recurrence only or
• the patient previously had a hysterectomy and relapsed with distant disease only or
• the patient previously had a hysterectomy and relapsed with both local recurrence and distant disease or
• the patient previously had locally advanced disease, did not have surgery and has relapsed with local recurrence only or
• the patient previously had locally advanced disease, did not have surgery and has relapsed with distant disease only or
• the patient previously had locally advanced disease, did not have surgery and has relapsed with both local recurrence and distant disease or
• the patient first presented with distant spread

4. The patient’s tumour has a documented presence of microsatellite instability-high (MSI-H) or DNA mismatch repair deficiency (dMMR) confirmed by validated testing.
5. The patient has progressive disease during or following previous platinum-based therapy for recurrent/locally advanced/metastatic endometrial carcinoma. Please mark below whether the patient has been previously treated with 1 course or >1 courses of treatment with platinum-based chemotherapy for recurrent/locally advanced/metastatic endometrial carcinoma:

• 1 previous course of treatment with platinum-based chemotherapy for recurrent/locally advanced/metastatic endometrial carcinoma or

• 1 previous courses of treatment with platinum-based chemotherapy for recurrent/locally advanced/metastatic endometrial carcinoma NB A course of treatment consists of a series of cycles of chemotherapy.

6. The patient has an ECOG performance status (PS) of 0 or 1.
7. The patient has no symptomatic brain or leptomeningeal metastases.
8. The patient has not received any prior treatment with an anti-PD-1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody for this endometrial cancer diagnosis.
9. Dostarlimab will be administered as monotherapy as follows: dostarlimab 500mg given for a maximum of 4 cycles every 3 weeks and then dostarlimab 1000mg is continued every 6 weeks.
10. Dostarlimab will be stopped after 3 years or on disease progression or unacceptable toxicity or withdrawal of patient consent, whichever occurs first.

Note

Note: once dostarlimab is stopped for one of the above reasons it cannot be re-started.

11. Where a treatment break of more than 12 weeks beyond the expected 3- or 6-weekly cycle length is needed for toxicity, I will complete a treatment break approval form to restart treatment, which MUST be approved before treatment with dostarlimab is recommenced.
12. Dostarlimab will be otherwise used as set out in its Summary of Product Characteristics (SPCs).

CDF funded From: 08 February 2022

Additional information

Form version: -

CDF Managed Access: Yes

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.406 of the CDF list, downloaded from NHS England’s website on 09 September 2026 at 21:36.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• DOS1_prior_to_cdf_1.361
• DOS1_prior_to_cdf_1.406